Caribou Biosciences (CRBU) investor relations material

Key insights and forward-looking statements

• Vispa-cel, an off-the-shelf CAR T-cell therapy for large B-cell lymphoma, shows efficacy and safety on par with autologous CAR T therapies, with potential for outpatient and community-based delivery.

• Approximately 60% of second-line large B-cell lymphoma patients are ineligible for both auto CAR T and stem cell transplant, highlighting a significant unmet need.

• The pivotal study for Vispa-cel will be a randomized controlled trial in second-line, dual-ineligible patients, focusing on those unable to access current curative options.

• ANTLER study data show high response rates and durable remissions, especially when using young donor T-cells, with manageable safety profiles similar to outpatient-approved therapies.

• The product's design and logistics could shift the treatment paradigm, enabling broader access and potentially reducing the need for autologous CAR T in both community and academic settings.

Barriers to access and patient perspectives

• Major barriers to CAR T access include geographic distance, referral challenges, rapid disease progression, and socioeconomic factors.

• Community oncologists report that 10–60% of eligible patients decline referral to academic centers, preferring local treatment due to convenience and support systems.

• Delays in manufacturing and insurance authorization for autologous CAR T can result in disease progression and missed treatment opportunities.

• Off-the-shelf CAR T offers rapid availability, which is critical for patients with aggressive disease or those unable to wait for autologous product manufacturing.

• Community centers are increasingly equipped to manage intensive regimens and CAR T-related toxicities, especially with experience from bispecific antibody programs.

Clinical and operational considerations

• Vispa-cel’s safety profile, including low rates of severe neurotoxicity and CRS, supports its use in outpatient and community settings, even for elderly or frail patients.

• Community oncologists express readiness to implement Vispa-cel, citing existing infrastructure and experience with similar therapies.

• Academic centers see value in off-the-shelf CAR T for patients with manufacturing failures, rapidly progressing disease, or logistical barriers.

• The pivotal trial will compare Vispa-cel to standard immunochemotherapy in a population with no current curative options, with endpoints including PFS, response, OS, QoL, and safety.

• Physicians anticipate that if Vispa-cel demonstrates non-inferiority or superiority to current options, it will be rapidly adopted and may coexist with autologous products.